1272P Updated Results from a First-in-human, Phase I/II Study of GB263T, a Novel EGFR/cMET/cMET Tri-Specific Antibody, in Patients with Advanced EGFR-mutated (egfrm) Non-Small Cell Lung Cancer (NSCLC)